March 17, 2020 / 10:58 AM / 13 days ago

BRIEF-Assertio Therapeutics Agrees To Merge With Zyla Life Sciences

March 17 (Reuters) - Assertio Therapeutics Inc:

* PRESS RELEASE - ASSERTIO THERAPEUTICS AGREES TO MERGE WITH ZYLA LIFE SCIENCES TO CREATE SYNERGISTIC PORTFOLIO OF NEUROLOGY AND NON-OPIOID PAIN PRODUCTS

* ASSERTIO THERAPEUTICS - SEES COMBINED COMPANY PRO FORMA 2019 NET PRODUCT SALES OF APPROXIMATELY $128 MILLION

* EXPECTS TO CAPTURE SIGNIFICANT OPERATING AND PRODUCT PORTFOLIO SYNERGIES UPWARDS OF $40 MILLION,

* ASSERTIO THERAPEUTICS - ARTHUR HIGGINS TO BECOME NON-EXECUTIVE CHAIRMAN AND TODD SMITH TO BE NAMED PRESIDENT AND CEO OF COMBINED COMPANY

* ASSERTIO THERAPEUTICS- ZYLA STOCKHOLDERS WILL RECEIVE 2.5 SHARES OF COMMON STOCK OF NEWLY-FORMED HOLDING CO FOR EACH SHARE OF ZYLA COMMON STOCK HELD

* NEWLY COMBINED COMPANY WILL RETAIN ASSERTIO NAME AND TRADE ON NASDAQ UNDER ASRT TICKER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below